|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM364726334 |
| 003 |
DE-627 |
| 005 |
20240410232305.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109843
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1371.xml
|
| 035 |
|
|
|a (DE-627)NLM364726334
|
| 035 |
|
|
|a (NLM)37981106
|
| 035 |
|
|
|a (PII)S1521-6616(23)00607-1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, WenHao
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Human monoclonal antibodies against Staphylococcus aureus A protein identified by high-throughput single-cell sequencing of phase I clinical volunteers' B cells
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.02.2024
|
| 500 |
|
|
|a Date Revised 10.04.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Methicillin-resistant Staphylococcus aureus, poses a significant threat through infections in both community and hospital settings. To address this challenge, we conducted a phase I clinical trial study involving a recombinant Staphylococcus aureus vaccine. Utilizing peripheral blood lymphocytes from 64 subjects, we isolated antigen-specific memory B cells for subsequent single-cell sequencing. Among the 676 identified antigen-binding IgG1+ clones, we selected the top 10 antibody strains for construction within expression vectors. Successful expression and purification of these monoclonal antibodies led to the discovery of a highly expressed human antibody, designated as IgG-6. This antibody specifically targets the pentameric form of the Staphylococcus aureus protein A (SpA5). In vivo assessments revealed that IgG-6 provided prophylactic protection against MRSA252 infection. This study underscores the potential of human antibodies as an innovative strategy against Staphylococcus aureus infections, offering a promising avenue for further research and clinical development
|
| 650 |
|
4 |
|a Clinical Trial, Phase I
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Human monoclonal antibody
|
| 650 |
|
4 |
|a Single-Cell Sequencing
|
| 650 |
|
4 |
|a Staphylococcus aureus
|
| 650 |
|
4 |
|a Staphylococcus aureus protein a
|
| 650 |
|
7 |
|a Antibodies, Bacterial
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 700 |
1 |
|
|a Gu, YaRu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ou, YangXue
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, JinRui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, BiXia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zuo, HouYi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Du, YeXiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Ying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tang, TengQian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zou, QuanMing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zuo, QianFei
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 257(2023) vom: 01. Dez., Seite 109843
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:257
|g year:2023
|g day:01
|g month:12
|g pages:109843
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109843
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 257
|j 2023
|b 01
|c 12
|h 109843
|